News and Announcements
ForgetSPECS is now PATENT APPROVED
- Published March 17, 2022 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
The CEO of ForgetSPECS Darrell Edwards is excited to announce the approval of the Australian Patent Application in the National Phase of International Application No.PCT/AU2018/000220. This paves the way for International patent applications already in progress in 33 countries across the globe.
This is a significant milestone proving that ForgetSpecs is novel, truly innovative and a unique solution to a growing global problem of eye disease.
Significantly, the dating to 2018 protects our designs and innovation priority.
Continued random testing has shown positive vision correction. The 5th generation prototypes are currently being produced in SE Asia.
ForgetSPECS is an innovative solution that enables people to use their smart devices – anywhere, anytime, without glasses. Our technology covers prescriptions from -3.5 to +3.5, (one screen suits all prescriptions within the range) just match the screen protector with your device make and model, align the lens and you will be able to see clearly. Using nanoimprint lithography, we have embedded over 3,000,000 tiny lenses into a film that changes the vergence of light emitted from the device. This adjusts the visual output to correct your eyesight. ForgetSPECS technology transforms a screen protector into a prescription lens, essentially making your glasses a part of your smart device.
The potential market size – the global spectacle lens market is expected to reach US$61.1B by 2026. The Global screen protector market is expected to reach US$76.64B by the end of 2028, with little differentiation.
The applications for ForgetSpecs technology are endless (smartphones, tablets, laptops, PCs, Watches, sports devices, vehicle navigation screens etc.)
The company is seeking investors and/or partners to accelerate commercialization.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
